Skip to Content

Ibritumomab Pregnancy and Breastfeeding Warnings

Ibritumomab is also known as: In-111 Zevalin, Y-90 Zevalin, Zevalin

Medically reviewed on October 23, 2017

Ibritumomab Pregnancy Warnings

Animal reproductive toxicology studies of this drug have not been conducted.

Immunoglobulins are known to cross the placenta. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use should be avoided.

US FDA pregnancy category: D

Risk Summary:
-This drug may cause fetal harm when administered to a pregnant woman.
-Potential fetal risk should be considered and informed if pregnancy occurs while receiving treatment with this drug.
-Encourage use of adequate methods of contraception during and for a minimum of 12 months following treatment.

See references

Ibritumomab Breastfeeding Warnings

A decision should be made to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

Comment:
-The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. In-111 Zevalin (ibritumomab)." IDEC Pharmaceuticals Corporation, San Diego, CA.

References for breastfeeding information

  1. "Product Information. In-111 Zevalin (ibritumomab)." IDEC Pharmaceuticals Corporation, San Diego, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide